Sirius XM and Merck released their latest earnings reports before opening bell this morning. Sirius XM reported $1.3 billion in revenue, which was in line with the consensus estimate. The satellite radio provider reported earnings of 4 cents per share, which was in line with consensus. In the same quarter a year ago, the company reported 3 cents per share on $1.2 billion in revenue.
Merck reported adjusted earnings of 89 cents per share, which was in line with the consensus estimate, on $10.12 billion in revenue, compared to the consensus of $10.23 billion. In the same quarter a year ago, the drug maker reported revenue of $10.22 billion.
Sirius XM beats estimate for subscriber adds
ARK Invest is known for targeting high-growth technology companies, with one of its most recent additions being DraftKings. In an interview with Maverick's Lee Ainslie at the Robinhood Investors Conference this week, Cathie Wood of ARK Invest discussed the firm's process and updated its views on some positions, including Tesla. Q1 2021 hedge fund letters, Read More
Sirius XM added $1.75 million subscribers last year, coming out head of the consensus of 1.65 million. The company had more than 31 million subscribers at the end of 2016. Self-pay net adds were 1.66 million last year, boosting self-pay subscribers to almost 26 million at the end of the year. Adjusted EBITDA rose 20% year over year in the fourth quarter, reaching $475 million. Average revenue per use ticked upward 3% to $12.91.
For 2017, Sirius XM expects about 1.3 million self-pay net subscriber adds and about $5.3 billion in revenue. The company looks for about $2.025 billion in adjusted EBITDA.
Shares of the company rose by as much as 0.84% to $4.81 in premarket trades this morning.
Merck’s GAAP earnings per share rose to 42 cents from 35 cents per share a year ago. Pharmaceutical sales fell 1% year over year to $8.9 billion in the fourth quarter. Animal health revenue, however, rose 6% to $884 million, beating the consensus of $867 million.
Singulair sales declined 23% to $210 million, while Januvia and Janumet sales ticked upward 4% to $1.5 billion. Keytruda sales surged 125% to $483 million. Gardasil sales rose 9% year over year to $542 million. Remicade sales fell 32% to $269 million.
Merck expects this year’s adjusted earnings to come in between $3.72 and $3.87 per share. The consensus currently stands at $3.83 per share. The Drug maker expects full-year revenue for this year to be between $38.6 billion and $40.1 billion, against the consensus of $40.1 billion.
Shares of the drug maker rose by as much as 1.03% to $62.74 in premarket trades this morning.